DoctorBox Includes Mainz Biomed’s ColoAlert(R) in Its Offerings

DNA-based Colorectal Cancer Screening Available as a Home Test

BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 — (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the inclusion of its ColoAlert® test in the portfolio of DoctorBox, one of Germany’s foremost innovators in digital health. This represents a significant achievement for Mainz Biomed’s European growth strategy and emphasizes the increasing importance of inventive, tailored solutions in preventive medicine. Laboratory analyses will be carried out by Mainz Biomed’s long-standing partner, the European Oncology Lab, headed by Dr. med. Annette Buhlmann in St. Ingbert, Germany.

Colorectal cancer is recognized as one of the most widespread yet preventable cancers globally. In Germany alone, roughly 60,000 new diagnoses are made each year—a clear indication of the pressing need for highly effective early detection measures. By integrating Mainz Biomed’s advanced DNA diagnostics into DoctorBox’s digital healthcare platform, this collaboration establishes an exceptionally innovative care model that can significantly broaden access to ColoAlert.

“Through DoctorBox, we are partnering with a strong ally that allows us to deliver ColoAlert precisely where prevention efforts can occur today—at home,” stated Guido Baechler, CEO of Mainz Biomed. “Together, we are diminishing obstacles to colorectal cancer screening and offering straightforward access to DNA-based early detection.”

“ColoAlert seamlessly integrates into our collection of next-generation DNA- and RNA-based tests. Consequently, innovative colorectal cancer screening becomes another foundational element of our digital preventive healthcare platform,” commented Julian Maar, CEO of DoctorBox.

The DoctorBox application centralizes contemporary preventive healthcare services onto a single platform. With over one million registered users and more than ten million test results transmitted, DoctorBox ranks among Europe’s leading digital prevention solutions. Its offerings include guideline-compliant preventive-care reminders, customized by age, sex, and risk profile. Additional services encompass at-home tests and locally available diagnostics, such as for the early detection of colorectal, cervical, and prostate cancer (available for self-pay or reimbursement). Provisions for sexual health, allergies, as well as advanced analyses, digital evaluation, and support—including the delivery of findings, actionable recommendations, and video consultations directly within the app—are also part of the DoctorBox suite.

To stay updated, please follow us:

About DoctorBox
DoctorBox is establishing the new benchmark for prevention in Europe—crafted in Germany.
As one of Germany’s premier digital solutions for intelligent preventive healthcare, DoctorBox empowers over one million users in Germany and other European nations to manage their health prevention simply, digitally, and independently.
Whether through reminders, home-based tests, or local diagnostics, DoctorBox makes preventive healthcare readily accessible and an integral part of everyday life.
To discover more, visit doctorbox.de.

About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently conducting its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex identification of molecular-genetic biomarkers in blood and stool samples.

To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media questions
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20

For investor questions, please reach out to 

Statements Regarding Future Prospects
This press release contains certain “forward-looking statements” as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements are often identifiable by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” as well as other similar phrases that forecast or suggest future occurrences or trends, rather than historical facts. These forward-looking statements are based on the current assessment of available information and are subject to various risks and uncertainties. Therefore, reliance on these statements should be exercised with caution. Actual outcomes may differ significantly from the Company’s expectations or forecasts due to identified and unidentified risks. Factors that could lead to actual results deviating materially from those outlined in these forward-looking statements include, but are not limited to: (i) an inability to achieve planned development and associated objectives; (ii) modifications in relevant laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its existing or target markets; and (iv) other inherent risks and uncertainties detailed herein, in addition to those discussed periodically in other reports and public filings with the Securities and Exchange Commission (the “SEC”) made by the Company. Further details regarding these and other factors that could influence the Company’s expectations and forecasts are available in its initial SEC filings, including its annual report on Form 20-F submitted on March 31, 2025, and its mid-year report on Form 6-K submitted on September 26, 2025. The Company’s SEC submissions are publicly accessible on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release reflects only the information currently accessible to Mainz Biomed and is valid solely as of its creation date. Mainz Biomed disclaims any obligation to publicly update any forward-looking statement, whether verbal or written, that may be made occasionally, whether due to new data, future developments, or otherwise, unless legally mandated.